Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMedMira Inc

MedMira Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.055 CAD 0.01 ( 10.00%)
Last update at 2026-11-03T15:23:00Z
VOLUME
23125
Market Cap
42.10M

Momentum Score

…

MedMira Inc., a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screening of HIV and hepatitis. It also provides the Miriad RVF toolkit, which facilitates the development and commercialization of rapid diagnostics; and Reveal G4 HIV tests. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.06
Low
0.06
High
52 Week Price Range
0.06
Low
0.11
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

MedMira Inc develops and commercializes rapid diagnostic tests and a proprietary point-of-care immunoassay platform for infectious disease screening and related quality-control products. Long-term growth may be supported by rising demand for decentralized testing, expansion into new indications, and licensing or distribution partnerships. Investors may find the company attractive because it occupies a niche diagnostics segment with a technology that could support recurring kit and control sales.

Key risks include limited scale and liquidity, reliance on regulatory approvals and partner agreements, competitive pressure from larger diagnostics firms, and execution and financing risk that could constrain growth.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.05
Dividend Yield
-
Revenue TTM
0.19M
Revenue Per Share
-
Gross Profit TTM
-0.65M
Debt / Equity
-
ROE
-
Net Debt
8.30M
ROCE
18.81%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Income before tax -4.52M -3.33M -2.68M -1.83M -0.68M
Net income -4.52M -3.33M -2.68M -1.83M -0.68M
Selling general administrative 1.61M 1.48M 0.84M 0.73M 0.49M
Selling and marketing expenses - - 0.20M 0.01M 0.04M
Gross profit 0.17M 0.23M 0.30M 0.30M 1.72M
Reconciled depreciation 0.32M 0.31M 0.21M 0.21M 0.21M
Ebit - - -1.79M -1.28M -0.02M
Ebitda - - -1.58M -1.07M 0.19M
Depreciation and amortization - - 0.21M 0.21M 0.21M
Operating income -3.45M -2.43M -1.94M -1.45M -0.18M
Other operating expenses - - 2.21M 2.22M 2.14M
Interest expense 1.08M 0.88M 0.89M 0.55M 0.65M
Net interest income -1.08M -0.90M -0.90M -0.56M -0.68M
Income tax expense - - 0.15M 0.17M 0.16M
Total revenue 0.24M 0.41M 0.43M 0.95M 2.14M
Total operating expenses 3.69M 2.84M 2.08M 1.57M 1.72M
Cost of revenue 0.07M 0.19M 0.13M 0.65M 0.42M
Total other income expense net - - -0.73M -0.38M -0.49M
Net income from continuing ops -4.52M -3.33M -2.68M -1.83M -0.68M
Net income applicable to common shares - - - -1.83M -0.68M
Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Total assets 3.68M 6.07M 3.65M 3.83M 3.89M
Intangible assets 0.00M 0.00M 0.00M 0.00M 0.00M
Total liab 26.24M 24.11M 18.68M 16.19M 19.61M
Total stockholder equity -22.56M -18.04M -15.03M -12.36M -15.72M
Other current liab 0.00M 0.00M - 0.61M 1.23M
Common stock - - - 68.35M 63.90M
Capital stock 68.67M 68.67M 68.35M 68.35M 63.90M
Retained earnings -105.81M -101.29M -97.96M -95.28M -93.45M
Cash 0.01M 2.10M 0.01M 0.03M -
Total current liabilities 22.02M 20.95M 15.73M 14.14M 17.41M
Net debt 8.30M 4.90M 7.25M 6.11M 9.23M
Short long term debt 6.30M 6.11M 6.14M 6.10M 9.19M
Other stockholder equity - - - 14.58M 13.82M
Property plant equipment - - - 2.17M 2.31M
Total current assets 1.60M 3.68M 1.69M 1.66M 1.58M
Net tangible assets - - - -12.36M -15.73M
Net receivables 1.32M 1.33M 1.26M 1.37M 1.25M
Long term debt 2.01M 0.89M 1.12M 0.04M 0.04M
Inventory 0.21M 0.18M 0.18M 0.20M 0.24M
Accounts payable 2.91M 2.72M 3.26M 2.75M 2.70M
Non current assets total 2.08M 2.39M 1.96M 2.17M 2.31M
Capital lease obligations 2.39M 2.56M 2.01M 2.16M 2.30M
Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Investments - -0.74M -0.00M -0.07M -0.04M
Change to liabilities - - - -0.57M 0.32M
Total cashflows from investing activities - - - -0.07M -0.04M
Net borrowings 1.02M 0.55M - 0.35M -0.37M
Total cash from financing activities 1.07M 5.77M 1.25M 1.99M 0.14M
Change to operating activities - - - 0.39M 0.70M
Net income -4.52M -3.33M -2.68M -1.83M -0.68M
Change in cash -2.08M 2.08M -0.02M 0.03M -0.40M
Begin period cash flow 2.10M 0.01M 0.03M 0.00M 0.40M
End period cash flow 0.01M 2.10M 0.01M 0.03M 0.00M
Total cash from operating activities -3.15M -2.94M -1.27M -1.88M -0.50M
Issuance of capital stock - - 0.00M 1.67M 0.52M
Depreciation 0.32M 0.31M 0.21M 0.21M 0.21M
Change to inventory -0.03M 0.00M 0.02M 0.03M -0.01M
Change to account receivables 0.01M -0.07M -0.01M 0.00M -1.04M
Other cashflows from financing activities - - 1.40M 0.53M 0.06M
Capital expenditures 0.01M 0.74M 0.00M 0.07M 0.04M
Change in working capital 0.94M 0.03M 1.20M -0.26M -0.04M
Other non cash items - 0.02M -0.05M 0.46M 1.09M
Free cash flow -3.15M -3.68M -1.27M -1.95M -0.54M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MIR
MedMira Inc		 0.01
10.00%		 0.06 - - 223.37 - 293.42 -80.03
SHRX
Sharp Therapeutics Corp.		 -
-%		 1.37 - - - 32.37 - -
NRX
NurExone Biologic Inc.		 -0.01
1.96%		 0.50 - 6.90 - 15.26 - -7.24
TTI
Thiogenesis Therapeutics Corp.		 0.01
1.61%		 0.63 - - - 15.17 - -58.16
ARCH
Arch Biopartners Inc		 0.01
1.27%		 0.80 - - 197.68 6211.54 53.05 6970.51

Profile*

MedMira Inc

MedMira Inc., a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screening of HIV and hepatitis. It also provides the Miriad RVF toolkit, which facilitates the development and commercialization of rapid diagnostics; and Reveal G4 HIV tests. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.

155 Chain Lake Drive, Halifax, NS, Canada, B3S 1B3

902 450 1588

https://medmira.com

Name Title Year Born
Mr. Hermes Chan Co-Founder, CEO, Pres & Director NA
Mr. Markus M. Meile Chief Financial Officer NA
Stewart McKelvey Legal Counsel NA
Dr. Kevin D. Jones Head of Commercialization and Sr. Director of Sales & Marketing 1969
Mr. Hermes Chan Co-Founder, CEO, President & Director NA
Dr. Sam Ratnam Director of Scientific & Regulatory Affairs NA
Dr. Kevin D. Jones Head of Commercialization and Senior Director of Sales & Marketing 1969

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

VNP
CAD 32.54
+24.44%
HUT
CAD 88.32
+14.81%
KEEL
CAD 3.05
+14.66%
MTY
CAD 36.63
+13.58%
CNL
CAD 15.98
+11.90%
MOON
CAD 4.72
-12.34%
EU
CAD 0.96
-8.57%
URE
CAD 1.02
-8.48%
AP-UN
CAD 3.71
-8.17%
HG
CAD 3.77
-8.05%

Equity Sectors*

  • Basic Materials

    -1.14%

  • Communication Services

    +0.65%

  • Consumer Cyclical

    +0.09%

  • Consumer Defensive

    -0.57%

  • Energy

    -0.15%

  • Financial Services

    +0.08%

  • Healthcare

    +2.18%

  • Industrials

    +2.04%

  • Real Estate

    -0.25%

  • Technology

    +1.02%

  • Utilities

    +0.66%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…